2023 World Conference on Lung Cancer (Posters)-P1.23. Clinical Utility of Combined Plasma and Tissue NGS in Patients with Advanced, Treatment-Naïve, Non-small Cell Lung Cancer

P1.23. Clinical Utility of Combined Plasma and Tissue NGS in Patients with Advanced, Treatment-Naïve, Non-small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This document discusses the clinical utility of combined plasma and tissue next-generation sequencing (NGS) in patients with advanced, treatment-naïve non-small cell lung cancer (NSCLC). The study aimed to determine the effectiveness of using both tissue and plasma NGS in detecting actionable genomic alterations in advanced NSCLC.<br /><br />The results of the study showed that tissue NGS detected 7-10% of actionable alterations that were not identified by ctDNA analysis, while plasma NGS detected 11-15% of actionable genomic aberrations that were undetectable by tissue analysis. Therefore, the use of both tissue and plasma NGS can increase the detection of actionable alterations in patients with newly diagnosed advanced NSCLC.<br /><br />The study also found that there were discrepancies in the data between tissue and plasma NGS. As a result, the authors recommend considering plasma NGS when actionable genomic alterations are not detected by tissue analysis, and vice versa.<br /><br />The document also notes that the incremental clinical value of performing both tissue and plasma NGS to detect actionable alterations in advanced NSCLC has not been comprehensively assessed. The study was conducted with two separate and clinically unselected cohorts of advanced NSCLC patients. Guardant360 CDx, FoundationOne Liquid and FoundationOne Liquid CDx, Oncomine Focus Assay (OFA), and Oncomine Precision Assay (OPA) were used for NGS analysis.<br /><br />Overall, the study suggests that combined tissue and plasma NGS have complementary roles in detecting actionable alterations in advanced NSCLC when these alterations are not detected by one of the assays alone. However, further research is needed to fully understand the clinical value of using both tissue and plasma NGS in the management of advanced NSCLC.

Asset Subtitle

Helena Bote de Cabo

Meta Tag

Speaker Helena Bote de Cabo

Topic Pathology & Biomarkers: Liquid Based Biomarkers

Keywords

clinical utility

combined plasma

tissue next-generation sequencing

advanced non-small cell lung cancer

treatment-naïve

actionable genomic alterations

ctDNA analysis

discrepancies

incremental clinical value

NGS analysis